Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1545 of 5804
-
New combo targets tough breast cancer in early trial
Disease control Recruiting nowThis is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Tears may hold key to ALS diagnosis, small study suggests
Diagnosis CompletedAmyotrophic Lateral Sclerosis (ALS) is the most common neurodegenerative disease affecting the motor neuron. Currently, there is no diagnostic test and no examination that can predict the evolution of this pathology. The search for diagnostic and prognostic biomarkers is therefor…
Phase: NA • Sponsor: University Hospital, Tours • Aim: Diagnosis
Last updated Jun 27, 2026 08:06 UTC
-
Can a shorter chemo regimen work just as well for some lymphoma patients?
Disease control Recruiting nowThe Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive, Low-risk, Non-mass Diffuse Large B-cell Lymphoma: a Multi-center, Prospective, Randomized Controlled Study
Phase: PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail aims to stall Hard-to-Treat gut tumors
Disease control Recruiting nowThis is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of small molecule kinase inhibitor or well-differentiate…
Phase: PHASE1, PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New shot may keep dialysis grafts open longer in kidney patients
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an arteriovenous graft (AVG). Data from this study will be used t…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could this pill slow Alzheimer's? new trial results are in
Disease control CompletedThe purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Exercise after heart procedure may help obese patients stay in rhythm
Disease control Recruiting nowImproving Outcomes After AF Ablation in Obese Patients
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for multiple myeloma: sonrotoclax trial targets resistant cancer
Disease control Recruiting nowThe purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alo…
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Magnetic pulses to the brain may ease fibromyalgia pain and help you walk better
Symptom relief CompletedFibromyalgia is a chronic condition that causes widespread pain and is often accompanied by fatigue, poor sleep, mood symptoms, memory and concentration difficulties, and reduced quality of life. Many adults with fibromyalgia also experience limitations in daily physical function…
Phase: NA • Sponsor: Institute of Rheumatology, Serbia • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New drug duo shows promise against tough cancers
Disease control CompletedThis study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced \[inoperable\] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.
Phase: PHASE1, PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo aims to boost lymphoma treatment
Disease control OngoingThis is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide…
Phase: PHASE1 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New Two-Drug combo pill shows promise for easier HIV management
Disease control OngoingThe safety and tolerability of MK-8591A, a 2-drug fixed dose combination (FDC) of doravirine (100mg) and islatravir (0.75mg) \[DOR/ISL 100 mg/0.75 mg) will be evaluated in participants with Human Immunodeficiency Virus -1 (HIV-1) who were treated with DOR and ISL in earlier clini…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Knee injection after ACL tear may stop arthritis before it starts
Prevention Recruiting nowAnterior cruciate ligament (ACL) injuries are extremely common. On average, 50% of individuals suffering an ACL injury will develop radiographic osteoarthritis (OA) 10 to 20 years after injury. Unfortunately, ACL reconstruction does not prevent risk of future OA. Interleukin-1 (…
Phase: EARLY_PHASE1 • Sponsor: University of California, Los Angeles • Aim: Prevention
Last updated Jun 27, 2026 08:15 UTC
-
One-and-Done radiation before lumpectomy? new trial tests feasibility
Disease control Recruiting nowThe GammaPod machine was made by Xcision Medical Systems and is already FDA cleared to deliver focused radiation within the breast. Unlike current radiation machines, the GammaPod was designed specifically for treating breast cancer. The GammaPod can pinpoint radiation to the tum…
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Mixing COVID-19 vaccines: could two different shots be better?
⭐️ VACCINE ⭐️ CompletedThis is a prospective, single blinded randomized homologous/heterologous prime-boost vaccine clinical study, designed to assess the immunogenicity of heterologous prime-boost immunization with AZD1222 and MVC-COV1901 in adults. Participants will be healthy adults at the age of 2…
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to strengthen bones in elderly women
Disease control OngoingThe purpose of this study is to find out if one year of romosozumab (Evenity®), a monthly injection given in the arm under the skin, prior to an infusion of zoledronic acid Reclast®, works to treat bone loss and prevent it from worsening in older women (ages 65 and older) who hav…
Phase: PHASE4 • Sponsor: Susan L. Greenspan • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Can a nasal spray and diabetes pill boost brain power?
Disease control CompletedThe proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin, to correct bioenergeti…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug ESG401 shows promise in early trial for advanced cancers
Disease control CompletedThe primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer. In Phase II, the primary objective is to evaluate the safety and eff…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 15:43 UTC
-
New antibiotic cocktail aims to beat infections in cancer patients
Disease control CompletedThis phase II trial studies the effect of imipenem-relebactam in treating patients with cancer who have a fever due to low white blood cell counts (febrile neutropenia). In this study, imipenem-relebactam will be compared to the standard-of-care treatment (cefepime, meropenem, or…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for rare bone cancer: trabectedin trial targets advanced disease
Disease control Recruiting nowProspective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)
Phase: PHASE2 • Sponsor: Italian Sarcoma Group • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC